Citurgia Biochemicals Q1FY27 Results: Loss narrows 68% YoY to ₹8.20 lakh
- Citurgia Biochemicals reported a Q1FY27 net loss of ₹8.20 lakh, down from ₹8.39 lakh YoY
- Total income from operations remained at zero for the quarter and full year
- Total expenses dropped 68% QoQ to ₹8.20 lakh due to lower other expenses
- Employee benefits stayed flat at ₹3.00 lakh; depreciation fell to ₹5.15 lakh
*this image is generated using AI for illustrative purposes only.
Citurgia Biochemicals Limited reported a standalone loss of ₹8.20 lakh for the quarter ended June 30, 2026 (Q1FY27). The loss narrowed significantly from ₹8.39 lakh in the corresponding quarter of FY26, driven by a reduction in operational expenses despite zero revenue generation.
The Mumbai-based biochemical firm disclosed zero total income from operations for Q1FY27, consistent with its performance in the preceding quarter and the full year ended March 31, 2026. The Board of Directors approved the unaudited financial results on August 14, 2026.
Financial Performance
The company’s expense structure contracted sharply in the current quarter compared to the previous period. Total expenses fell to ₹8.20 lakh from ₹25.82 lakh in Q4FY26. This decline was primarily attributable to lower other expenses, which dropped to ₹0.05 lakh from ₹14.15 lakh in the preceding quarter.
Employee benefit expenses remained stable at ₹3.00 lakh, while depreciation and amortisation costs decreased slightly to ₹5.15 lakh from ₹5.73 lakh. For the full fiscal year 2026, the company incurred a total loss of ₹74.25 lakh against nil revenue.
| Metric | Q1FY27 | Q4FY26 | Q1FY26 |
|---|---|---|---|
| Total Income from Operations | ₹0.00 lakh | ₹0.00 lakh | ₹0.00 lakh |
| Total Expenses | ₹8.20 lakh | ₹25.82 lakh | ₹8.39 lakh |
| Net Loss | ₹8.20 lakh | ₹25.82 lakh | ₹8.39 lakh |
What the Numbers Show
The absence of any operating income or other income indicates that the company is not currently generating cash flows from business activities. The profit before tax matches the total expenses exactly, confirming that the entire loss is driven by fixed overheads such as employee benefits and depreciation rather than variable costs linked to production or sales volume.
Historical Stock Returns for Krebs Biochemicals & Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.32% | +0.78% | +3.07% | +5.04% | -21.75% | -62.76% |
What is Citurgia Biochemicals' strategic roadmap for resuming revenue-generating operations, and when does management expect the first commercial sales?
Given the persistent zero-revenue status, what are the company's current cash reserves, and how long can they sustain operations without additional capital infusion or equity dilution?
How does the significant reduction in 'other expenses' reflect changes in corporate strategy, such as asset write-downs or legal settlements, rather than just operational efficiency?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
